Breaking News Instant updates and real-time market news.

ATNF

180 Life Sciences

$2.16 /

-0.28 (-11.48%)

08:41
11/17/20
11/17
08:41
11/17/20
08:41

180 Life Sciences CEO expects operating expenses to remain low relative to peers

180 Life Sciences Corp. released the following letter to stockholders from its CEO Dr. James Woody. The letter read in part, "On the heels of the November 9, 2020, closing of our merger with KBLM Merger Corp IV, resulting in 180 Life Sciences now being a stand-alone publicly traded company and its common stock being listed on The NASDAQ Capital Market under the symbol "ATNF", I wanted to take this opportunity to personally communicate with you. It goes without saying that I appreciate your support in helping us get to where we are today and want to update you on our planned path moving forward...I'd like to now tell you a little about our exciting pipeline which includes three clinical programs addressing the following indications: Early Dupuytren's contracture, a fibrotic disease of the hand, which is in Phase 2b/3, with results expected in 2H 2021. Dupuytren's disease is estimated to impact over 11 million Americans, and about the same number in the European Union. Our trial is focused on treating early and preventing the progress of the disease to avoid the hand contracture disability. This project is entirely grant funded. Frozen shoulder, with a grant to initiate the clinical study recently awarded by the National Institute of Health Research, U.K. Due to COVID-19, we plan to start the trial in Q3 2021. Again, we plan to try and avoid the pain and disability associated with Frozen Shoulder by treating early. Post-operative cognitive delirium disorder and dysfunction, a major unmet clinical need occurring in the elderly patient population, most commonly following lengthy anesthesia during hip fracture repair or after CABG. We hope to be able to reduce or prevent this dysfunction. Additionally, our pre-clinical discovery programs include: A program focused on the development of unique, Food and Drug Administration-approved, pharmaceutical-grade oral synthetic cannabidiol analogs to treat pain that is specifically focused on arthritis. This project is run in Israel and Oxford, England. We are working with one of the foremost authorities on Cannabis chemistry and the discoverer of the body's own "cannabinoids", Prof Raphael Mechoulam. To optimize uptake we are working with an expert in cannabinoid drug delivery, Prof Avi Domb in Jerusalem, Israel. The alpha7nAChR program, which aims to develop alpha7nAChR agonists for the treatment of inflammatory diseases, initially ulcerative colitis induced after cessation of smoking. We look forward to the results of our Phase 2b/3 study on Dupuytren's contracture, a disease that impacts a large total addressable market estimated to comprise over 22 million in the US and EU. We believe that if we are able to successfully commercialize this drug, of which there can be no assurance, it has the potential to generate significant revenues for the Company. It is important to note that our business model itself is unique for a biotech company. Almost all our clinical studies to date have been funded in full through grants. While ultimately, we intend to fund some studies internally, we anticipate our operating expenses will remain low relative to our peers. There are many advantages of doing clinical development mostly with academic leaders, both in cost, efficiency and credibility. I'd like to close by telling you why I took the role as CEO and what my personal goal is for the Company. My goal and the goal of the other members of management is to build stockholder value by developing world leading products to solve unmet medical needs. As management and insiders currently own over 50% of the Company, we believe our goals are directly aligned with the stockholders of the Company. Many members of our management team have not taken a salary to date. Future compensation will be conservative, favoring equity over cash."

TODAY'S FREE FLY STORIES

Syndicate
iCAD 1.222M share Spot Secondary priced at $18.00 » 06:28
03/03/21
03/03
06:28
03/03/21
06:28
ICAD

iCAD

$18.88 /

-0.3 (-1.56%)

The deal size was…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
ICAD iCAD
$18.88 /

-0.3 (-1.56%)

ICAD iCAD
$18.88 /

-0.3 (-1.56%)

02/26/21 B. Riley Securities
iCAD price target raised to $23 from $18 at B. Riley Securities
02/25/21 Oppenheimer
iCAD initiated with an Outperform at Oppenheimer
02/25/21 Craig-Hallum
iCAD price target raised to $22 from $15 at Craig-Hallum
02/25/21 Lake Street
iCAD price target raised to $21 from $17 at Lake Street
ICAD iCAD
$18.88 /

-0.3 (-1.56%)

  • 03
    Mar
ICAD iCAD
$18.88 /

-0.3 (-1.56%)

Upgrade
Julius Baer upgraded to Buy from Hold at HSBC » 06:27
03/03/21
03/03
06:27
03/03/21
06:27
JBAXY

Julius Baer

$0.00 /

+ (+0.00%)

HSBC analyst Piers Brown…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
JBAXY Julius Baer
$0.00 /

+ (+0.00%)

05:28 Today HSBC
Julius Baer upgraded to Buy from Hold at HSBC
02/02/21 JPMorgan
Julius Baer price target raised to CHF 63 from CHF 57 at JPMorgan
02/02/21 RBC Capital
Julius Baer price target raised to CHF 64 from CHF 55 at RBC Capital
12/17/20 JPMorgan
Julius Baer price target raised to CHF 57 from CHF 50 at JPMorgan
Initiation
Nice assumed with a Buy at Citi » 06:27
03/03/21
03/03
06:27
03/03/21
06:27
NICE

Nice

$227.25 /

-3.265 (-1.42%)

Citi analyst Tyler Radke…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
NICE Nice
$227.25 /

-3.265 (-1.42%)

NICE Nice
$227.25 /

-3.265 (-1.42%)

02/19/21 Jefferies
Nice should be bought on post-earnings weakness, says Jefferies
02/19/21 Citi
Nice price target raised to $312 from $292 at Citi
02/19/21 RBC Capital
Nice price target raised to $266 from $250 at RBC Capital
02/11/21 Oppenheimer
Nice assumed with an Outperform at Oppenheimer
NICE Nice
$227.25 /

-3.265 (-1.42%)

Syndicate
Heska 941K share Secondary priced at $186.00 » 06:26
03/03/21
03/03
06:26
03/03/21
06:26
HSKA

Heska

$189.61 /

-11.69 (-5.81%)

The deal size was…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
HSKA Heska
$189.61 /

-11.69 (-5.81%)

HSKA Heska
$189.61 /

-11.69 (-5.81%)

02/24/21 Alliance Global Partners
Heska price target raised to $230 from $167.50 at Alliance Global Partners
02/23/21 Piper Sandler
Heska price target raised to $220 from $157 at Piper Sandler
01/29/21 JPMorgan
Heska initiated with an Overweight at JPMorgan
11/23/20 Piper Sandler
Heska price target raised to $157 from $150 at Piper Sandler
HSKA Heska
$189.61 /

-11.69 (-5.81%)

  • 03
    Mar
Upgrade
Spin Master upgraded to Outperform from Sector Perform at RBC Capital » 06:26
03/03/21
03/03
06:26
03/03/21
06:26
SNMSF

Spin Master

/

+

RBC Capital analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
SNMSF Spin Master
/

+

03/02/21 RBC Capital
Spin Master upgraded to Outperform from Sector Perform at RBC Capital
03/02/21 Stifel
Spin Master upgraded to Buy from Hold at Stifel
03/02/21 Stifel
Spin Master upgraded to Buy from Hold at Stifel
01/25/21 CIBC
Spin Master price target lowered to C$33 from C$35 at CIBC
SNMSF Spin Master
/

+

Initiation
Microsoft assumed with a Buy at Citi » 06:26
03/03/21
03/03
06:26
03/03/21
06:26
MSFT

Microsoft

$233.90 /

-2.98 (-1.26%)

Citi analyst Tyler Radke…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
MSFT Microsoft
$233.90 /

-2.98 (-1.26%)

MSFT Microsoft
$233.90 /

-2.98 (-1.26%)

02/16/21 Wedbush
Microsoft price target raised to $300 from $285 at Wedbush
02/16/21 UBS
Workday price target raised to $280 from $235 at UBS
02/08/21 KeyBanc
Viva reinforces Microsoft Office/Teams innovation commitment, says KeyBanc
02/08/21 RBC Capital
Datadog price target raised to $110 from $85 at RBC Capital
MSFT Microsoft
$233.90 /

-2.98 (-1.26%)

MSFT Microsoft
$233.90 /

-2.98 (-1.26%)

MSFT Microsoft
$233.90 /

-2.98 (-1.26%)

MSFT Microsoft
$233.90 /

-2.98 (-1.26%)

Downgrade
Wizz Air downgraded to Reduce from Hold at HSBC » 06:26
03/03/21
03/03
06:26
03/03/21
06:26
WZZAF

Wizz Air

$0.00 /

+ (+0.00%)

HSBC analyst Andrew…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
WZZAF Wizz Air
$0.00 /

+ (+0.00%)

02/24/21 Citi
Wizz Air price target raised to 6,000 GBp at Citi
02/12/21 Credit Suisse
Wizz Air price target raised to 5,788 GBp from 4,889 GBp at Credit Suisse
02/10/21 Exane BNP Paribas
Wizz Air downgraded to Underperform from Neutral at Exane BNP Paribas
01/20/21 Barclays
Wizz Air price target raised to 4,880 GBp from 3,785 GBp at Barclays
Initiation
HubSpot assumed with a Buy at Citi » 06:25
03/03/21
03/03
06:25
03/03/21
06:25
HUBS

HubSpot

$517.33 /

-8.965 (-1.70%)

Citi analyst Tyler Radke…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
HUBS HubSpot
$517.33 /

-8.965 (-1.70%)

HUBS HubSpot
$517.33 /

-8.965 (-1.70%)

02/22/21 Argus
HubSpot price target raised to $625 from $435 at Argus
02/12/21 Needham
HubSpot price target raised to $520 from $400 at Needham
02/12/21 Cowen
HubSpot price target raised to $510 from $400 at Cowen
02/12/21 Raymond James
HubSpot upgraded to Strong Buy from Outperform at Raymond James
HUBS HubSpot
$517.33 /

-8.965 (-1.70%)

HUBS HubSpot
$517.33 /

-8.965 (-1.70%)

HUBS HubSpot
$517.33 /

-8.965 (-1.70%)

Syndicate
Cardlytics 3.85M share Secondary priced at $130.00 » 06:25
03/03/21
03/03
06:25
03/03/21
06:25
CDLX

Cardlytics

$134.04 /

-7.16 (-5.07%)

BofA, JPMorgan, Wells…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
CDLX Cardlytics
$134.04 /

-7.16 (-5.07%)

CDLX Cardlytics
$134.04 /

-7.16 (-5.07%)

03/02/21 Truist
Cardlytics price target raised to $150 from $90 at Truist
03/01/21 Truist
Cardlytics price target raised to $150 from $90 at Truist
01/14/21 William Blair
Cardlytics downgraded to Market Perform on valuation at William Blair
01/14/21 William Blair
Cardlytics downgraded to Market Perform from Outperform at William Blair
CDLX Cardlytics
$134.04 /

-7.16 (-5.07%)

  • 03
    Mar
Initiation
Fastly assumed with a Sell at Citi » 06:24
03/03/21
03/03
06:24
03/03/21
06:24
FSLY

Fastly

$70.91 /

-6.42 (-8.30%)

Citi analyst Tyler Radke…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
FSLY Fastly
$70.91 /

-6.42 (-8.30%)

FSLY Fastly
$70.91 /

-6.42 (-8.30%)

02/18/21 Raymond James
Fastly price target raised to $95 from $85 at Raymond James
01/22/21 Piper Sandler
Fastly 2021 sales guidance to miss expectations, says Piper Sandler
01/21/21
Fly Intel: Top five analyst upgrades
01/21/21 Oppenheimer
Fastly upgraded to Outperform at Oppenheimer
FSLY Fastly
$70.91 /

-6.42 (-8.30%)

  • 21
    May
FSLY Fastly
$70.91 /

-6.42 (-8.30%)

FSLY Fastly
$70.91 /

-6.42 (-8.30%)

FSLY Fastly
$70.91 /

-6.42 (-8.30%)

Upgrade
Europcar Mobility upgraded to Hold from Reduce at HSBC » 06:24
03/03/21
03/03
06:24
03/03/21
06:24
EURMF

Europcar Mobility

$0.00 /

+ (+0.00%)

HSBC analyst Joseph…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
EURMF Europcar Mobility
$0.00 /

+ (+0.00%)

05:29 Today HSBC
Europcar Mobility upgraded to Hold from Reduce at HSBC
Syndicate
Oscar Health 31M share IPO priced at $39.00 » 06:24
03/03/21
03/03
06:24
03/03/21
06:24
OSCR

Oscar Health

$0.00 /

+ (+0.00%)

The deal priced above the…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
  • 03
    Mar
OSCR Oscar Health
$0.00 /

+ (+0.00%)

Initiation
Dynatrace assumed with a Buy at Citi » 06:23
03/03/21
03/03
06:23
03/03/21
06:23
DT

Dynatrace

$52.20 /

-1.14 (-2.14%)

Citi analyst Tyler Radke…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
DT Dynatrace
$52.20 /

-1.14 (-2.14%)

DT Dynatrace
$52.20 /

-1.14 (-2.14%)

02/04/21
Dynatrace price target raised to $50 from $40 at Loop Capital
02/04/21
Dynatrace price target raised to $65 from $50 at DA Davidson
02/04/21 JPMorgan
Dynatrace price target raised to $67 from $50 at JPMorgan
02/04/21
Dynatrace price target raised to $60 from $50 at Truist
DT Dynatrace
$52.20 /

-1.14 (-2.14%)

  • 09
    Dec
  • 03
    Aug
  • 03
    Jun
DT Dynatrace
$52.20 /

-1.14 (-2.14%)

Initiation
DocuSign assumed with a Buy at Citi » 06:22
03/03/21
03/03
06:22
03/03/21
06:22
DOCU

DocuSign

$232.46 /

-6.16 (-2.58%)

Citi analyst Tyler Radke…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
DOCU DocuSign
$232.46 /

-6.16 (-2.58%)

DOCU DocuSign
$232.46 /

-6.16 (-2.58%)

02/17/21 Wedbush
DocuSign price target raised to $300 from $270 at Wedbush
02/03/21 Piper Sandler
Piper raises 'bull-case' for DocuSign to $375, calls top idea for 2021
01/05/21 Piper Sandler
DocuSign upgraded on 'sticky' e-signature demand at Piper Sandler
01/04/21 Piper Sandler
DocuSign upgraded to Overweight from Neutral at Piper Sandler
DOCU DocuSign
$232.46 /

-6.16 (-2.58%)

DOCU DocuSign
$232.46 /

-6.16 (-2.58%)

DOCU DocuSign
$232.46 /

-6.16 (-2.58%)

DOCU DocuSign
$232.46 /

-6.16 (-2.58%)

Syndicate
Aslan Pharmaceuticals 15M share Secondary priced at $4.00 » 06:22
03/03/21
03/03
06:22
03/03/21
06:22
ASLN

Aslan Pharmaceuticals

$4.34 /

-0.88 (-16.86%)

Jefferies and Piper…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
ASLN Aslan Pharmaceuticals
$4.34 /

-0.88 (-16.86%)

ASLN Aslan Pharmaceuticals
$4.34 /

-0.88 (-16.86%)

03/01/21 Piper Sandler
Piper boosts Aslan target to $10 after positive atopic dematitis data
04/13/20 Piper Sandler
Aslan interim data for ASLN004 study still expected in 2020, says Piper Sandler
03/18/20 Piper Sandler
Aslan Pharmaceuticals price target lowered to $6 from $8 at Piper Sandler
ASLN Aslan Pharmaceuticals
$4.34 /

-0.88 (-16.86%)

  • 03
    Mar
ASLN Aslan Pharmaceuticals
$4.34 /

-0.88 (-16.86%)

Initiation
Citrix assumed with a Buy at Citi » 06:21
03/03/21
03/03
06:21
03/03/21
06:21
CTXS

Citrix

/

+

Citi analyst Tyler Radke…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
CTXS Citrix
/

+

CTXS Citrix
/

+

01/20/21 RBC Capital
Citrix price target raised to $150 from $145 at RBC Capital
01/20/21 Citi
Citrix shares remain 'attractively priced,' says Citi
10/23/20 Morgan Stanley
Citrix downgraded to Equal Weight on slower cloud progress at Morgan Stanley
10/23/20 RBC Capital
Citrix price target lowered to $145 from $162 at RBC Capital
CTXS Citrix
/

+

CTXS Citrix
/

+

Recommendations
International Game price target raised to $25 from $22 at Macquarie » 06:21
03/03/21
03/03
06:21
03/03/21
06:21
IGT

International Game

$18.37 /

-0.37 (-1.97%)

Macquarie analyst Chad…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
IGT International Game
$18.37 /

-0.37 (-1.97%)

IGT International Game
$18.37 /

-0.37 (-1.97%)

01/19/21 Jefferies
International Game upgraded to Buy from Hold at Jefferies
01/14/21 Truist
International Game upgraded to Buy from Hold at Truist
01/12/21 Argus
International Game upgraded to Buy from Hold at Argus
01/07/21 Deutsche Bank
International Game price target raised to $25 from $16 at Deutsche Bank
IGT International Game
$18.37 /

-0.37 (-1.97%)

IGT International Game
$18.37 /

-0.37 (-1.97%)

IGT International Game
$18.37 /

-0.37 (-1.97%)

Initiation
Adobe assumed with a Neutral at Citi » 06:20
03/03/21
03/03
06:20
03/03/21
06:20
ADBE

Adobe

$466.72 /

-3.6 (-0.77%)

Citi analyst Tyler Radke…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
ADBE Adobe
$466.72 /

-3.6 (-0.77%)

ADBE Adobe
$466.72 /

-3.6 (-0.77%)

02/03/21 Wedbush
Adobe price target raised to $510 from $410 at Wedbush
01/21/21 Goldman Sachs
Adobe initiated with a Buy at Goldman Sachs
01/13/21 Stifel
Adobe transferred with Buy rating at Stifel
12/11/20 BMO Capital
Adobe price target raised to $570 from $560 at BMO Capital
ADBE Adobe
$466.72 /

-3.6 (-0.77%)

ADBE Adobe
$466.72 /

-3.6 (-0.77%)

ADBE Adobe
$466.72 /

-3.6 (-0.77%)

ADBE Adobe
$466.72 /

-3.6 (-0.77%)

Periodicals
Samsung eyes four sites in U.S. for new $17B chip plant, Reuters reports » 06:19
03/03/21
03/03
06:19
03/03/21
06:19
SSNLF

Samsung

$0.00 /

+ (+0.00%)

Samsung Electronics is…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
SSNLF Samsung
$0.00 /

+ (+0.00%)

SSNLF Samsung
$0.00 /

+ (+0.00%)

02/04/21 Craig-Hallum
Qorvo price target raised to $195 from $160 at Craig-Hallum
02/04/21 Craig-Hallum
Digital Turbine price target raised to $80 from $60 at Craig-Hallum
01/29/21 Needham
Skyworks price target raised to $245 from $200 at Needham
01/26/21
Applied Materials upgraded to Buy at DA Davidson on semicap strength
SSNLF Samsung
$0.00 /

+ (+0.00%)

SSNLF Samsung
$0.00 /

+ (+0.00%)

SSNLF Samsung
$0.00 /

+ (+0.00%)

Initiation
Atlassian assumed with a Buy at Citi » 06:19
03/03/21
03/03
06:19
03/03/21
06:19
TEAM

Atlassian

$244.40 /

-7.25 (-2.88%)

Citi analyst Tyler Radke…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
TEAM Atlassian
$244.40 /

-7.25 (-2.88%)

TEAM Atlassian
$244.40 /

-7.25 (-2.88%)

01/29/21 DA Davidson
Atlassian price target raised to $275 from $235 at DA Davidson
01/29/21 BMO Capital
Atlassian price target raised to $260 from $235 at BMO Capital
01/29/21 Canaccord
Atlassian price target raised to $260 from $225 at Canaccord
01/29/21 Cowen
Atlassian price target raised to $255 from $250 at Cowen
TEAM Atlassian
$244.40 /

-7.25 (-2.88%)

TEAM Atlassian
$244.40 /

-7.25 (-2.88%)

TEAM Atlassian
$244.40 /

-7.25 (-2.88%)

Downgrade
Associated British Foods downgraded to Sell from Neutral at Redburn » 06:17
03/03/21
03/03
06:17
03/03/21
06:17
ASBFY

Associated British Foods

$0.00 /

+ (+0.00%)

Redburn analyst Emily…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
ASBFY Associated British Foods
$0.00 /

+ (+0.00%)

05:11 Today Redburn
Associated British Foods downgraded to Sell from Neutral at Redburn
02/26/21 Barclays
Associated British Foods price target raised to 2,700 GBp from 2,600 GBp at Barclays
02/23/21 Grupo Santander
Associated British Foods upgraded to Buy from Hold at Grupo Santander
01/21/21 Berenberg
Associated British Foods price target raised to 2,650 GBp at Berenberg
Hot Stocks
Patterson-UTI reports an average of 69 drilling rigs operating in February » 06:17
03/03/21
03/03
06:17
03/03/21
06:17
PTEN

Patterson-UTI

$7.57 /

-0.305 (-3.87%)

Patterson-UTI reported…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
PTEN Patterson-UTI
$7.57 /

-0.305 (-3.87%)

PTEN Patterson-UTI
$7.57 /

-0.305 (-3.87%)

12/15/20 Citi
Patterson-UTI price target raised to $6 from $3 at Citi
11/30/20 Susquehanna
Susquehanna raises targets across Oilfield Services on cyclical rebound
07/16/20 Scotiabank
Patterson-UTI downgraded to Underperform from Sector Perform at Scotiabank
05/28/20 Citi
Patterson-UTI price target raised to $4.50 from $1.90 at Citi
PTEN Patterson-UTI
$7.57 /

-0.305 (-3.87%)

Hot Stocks
U.S. District Court rules in AstraZeneca's favor in Symbicort patent litigation » 06:17
03/03/21
03/03
06:17
03/03/21
06:17
AZN

AstraZeneca

$47.72 /

-0.38 (-0.79%)

, MMM

3M

$177.16 /

+0.78 (+0.44%)

, VTRS

Viatris

$14.28 /

-0.46 (-3.12%)

The company states:…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
AZN AstraZeneca
$47.72 /

-0.38 (-0.79%)

MMM 3M
$177.16 /

+0.78 (+0.44%)

VTRS Viatris
$14.28 /

-0.46 (-3.12%)

AZN AstraZeneca
$47.72 /

-0.38 (-0.79%)

02/25/21
Fly Intel: Top five analyst upgrades
02/25/21 UBS
AstraZeneca upgraded to Buy from Neutral at UBS
02/04/21 Piper Sandler
Alexion downgraded to Neutral ahead of expected deal closing at Piper Sandler
02/01/21 BofA
BofA downgrades Moderna to Underperform, sees shares priced for 'best-case'
MMM 3M
$177.16 /

+0.78 (+0.44%)

02/03/21
Fly Intel: Top five analyst upgrades
02/03/21 Argus
3M upgraded to Buy from Hold at Argus
02/03/21 Argus
3M upgraded to Buy from Hold at Argus
01/27/21 Credit Suisse
3M price target lowered to $197 from $208 at Credit Suisse
VTRS Viatris
$14.28 /

-0.46 (-3.12%)

03/02/21 JPMorgan
Viatris downgraded to Neutral on 'modest' growth at JPMorgan
03/02/21 JPMorgan
Viatris downgraded to Neutral from Overweight at JPMorgan
02/26/21 Wolfe Research
Viatris downgraded to Peer Perform from Outperform at Wolfe Research
02/23/21 Barclays
Viatris price target lowered to $20 from $26 at Barclays
AZN AstraZeneca
$47.72 /

-0.38 (-0.79%)

MMM 3M
$177.16 /

+0.78 (+0.44%)

VTRS Viatris
$14.28 /

-0.46 (-3.12%)

AZN AstraZeneca
$47.72 /

-0.38 (-0.79%)

MMM 3M
$177.16 /

+0.78 (+0.44%)

AZN AstraZeneca
$47.72 /

-0.38 (-0.79%)

MMM 3M
$177.16 /

+0.78 (+0.44%)

AZN AstraZeneca
$47.72 /

-0.38 (-0.79%)

MMM 3M
$177.16 /

+0.78 (+0.44%)

VTRS Viatris
$14.28 /

-0.46 (-3.12%)

Recommendations
Veeva price target raised to $350 from $340 at Piper Sandler » 06:16
03/03/21
03/03
06:16
03/03/21
06:16
VEEV

Veeva

$288.36 /

-5.21 (-1.77%)

Piper Sandler analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
VEEV Veeva
$288.36 /

-5.21 (-1.77%)

VEEV Veeva
$288.36 /

-5.21 (-1.77%)

02/17/21 KeyBanc
Veeva price target raised to $353 from $332 at KeyBanc
01/13/21 Citi
Elastic price target raised to $190 from $160 at Citi
01/11/21 Piper Sandler
Veeva price target raised to $340 from $310 at Piper Sandler
01/11/21 Piper Sandler
Bill.com price target raised to $140 from $120 at Piper Sandler
VEEV Veeva
$288.36 /

-5.21 (-1.77%)

VEEV Veeva
$288.36 /

-5.21 (-1.77%)

Earnings
AES Corp. backs FY21 adjusted EPS view $1.50-$1.58, consensus $1.56 » 06:15
03/03/21
03/03
06:15
03/03/21
06:15
AES

AES Corp.

$26.82 /

-0.18 (-0.67%)

Sees FY21 parent free…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
AES AES Corp.
$26.82 /

-0.18 (-0.67%)

AES AES Corp.
$26.82 /

-0.18 (-0.67%)

01/11/21 BofA
BofA US 1 List changes
09/18/20 Morgan Stanley
AES Corp. price target raised to $23.50 from $19 at Morgan Stanley
08/13/20 BofA
AES Corp. added to US 1 List; Ameren removed at BofA
05/20/20 Seaport Global
Seaport Global starts power and competitive retail sector with positive outlook
AES AES Corp.
$26.82 /

-0.18 (-0.67%)

AES AES Corp.
$26.82 /

-0.18 (-0.67%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.